[HTML][HTML] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow… - Endocrine-related …, 2009 - erc.bioscientifica.com
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of∼ 4 months has not changed in …
has improved locoregional control, the median survival of∼ 4 months has not changed in …
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.
RC Smallridge, LA Marlow, JA Copland - Endocrine-related Cancer, 2008 - europepmc.org
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of~ 4 months has not changed in …
has improved locoregional control, the median survival of~ 4 months has not changed in …
[HTML][HTML] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow… - Endocrine-Related …, 2009 - erc.bioscientifica.com
It is generally assumed that the development of testicular germ cell tumor (TGCT) is under
endocrine control. In particular, unbalanced androgen/estrogen levels and/or activity are …
endocrine control. In particular, unbalanced androgen/estrogen levels and/or activity are …
[引用][C] ANAPLASTIC THYROID CANCER: MOLECULAR PATHOGENESIS AND EMERGING THERAPIES
RC SMALLRIDGE, LA MARLOW, JA COPLAND - 2009 - sid.ir
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow… - Endocrine-related …, 2009 - pubmed.ncbi.nlm.nih.gov
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of approximately 4 months has not …
has improved locoregional control, the median survival of approximately 4 months has not …
[PDF][PDF] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow, JA Copland - Endocrine-Related Cancer, 2009 - Citeseer
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of w 4 months has not changed in …
has improved locoregional control, the median survival of w 4 months has not changed in …
[HTML][HTML] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow, JA Copland - Endocrine-related cancer, 2009 - ncbi.nlm.nih.gov
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of∼ 4 months has not changed in …
has improved locoregional control, the median survival of∼ 4 months has not changed in …
Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow… - Endocrine-Related …, 2009 - mayoclinic.elsevierpure.com
Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of∼ 4 months has not changed in …
has improved locoregional control, the median survival of∼ 4 months has not changed in …
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
RC Smallridge, LA Marlow, JA Copland - Endocrine-Related Cancer, 2009 - cir.nii.ac.jp
抄録< jats: p> Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam
radiation therapy has improved locoregional control, the median survival of∼ 4 months has …
radiation therapy has improved locoregional control, the median survival of∼ 4 months has …
[引用][C] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
R CS - Endocr Relat Cancer, 2009 - cir.nii.ac.jp